Epperly Melissa B sold $196k of ROIV
director at Roivant Sciences Ltd.. 4,938 shares at an average of $39.74, traded Sep 15, 2026, filed Sep 17, 2026.
Score components
- +15RoleDirector
- +12Trade size$196k at market
- +10Share of holdings soldSold 33% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001807359-26-000014, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | SOpen-market sale Common Shares10b5-1 | -4,338 | $39.65 | $172k | 10,500 | 26 d ago |
| Sep 15, 2026 | SOpen-market sale Common Shares10b5-1 | -600 | $40.38 | $24k | 9,900 | 26 d ago |
Related signals
Other insiders at Roivant Sciences Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 28Weak | Roivant Sciences Ltd. | Epperly Melissa B director | $641k 17,750 shares | -54% | |
| 28Weak | Roivant Sciences Ltd. | Eric Venker President & Immunovant CEO | $7.3M 200,000 shares | -11% | |
| 20Weak | Roivant Sciences Ltd. | Meghan Fitzgerald director | $203k 5,112 shares | -12% | |
| 27Weak | Roivant Sciences Ltd. | Meghan Fitzgerald director | $798k 20,000 shares | -32% | |
| 28Weak | Roivant Sciences Ltd. | Eric Venker President & Immunovant CEO | $7.2M 200,000 shares | -11% | |
| 48Moderate | Roivant Sciences Ltd. | Daniel Allen Gold director | $49M 1,438,163 shares | -10% | |
| 53Moderate | Roivant Sciences Ltd. | Keith S Manchester director | $56M 1,638,163 shares | -11% | |
| 58Moderate | Roivant Sciences Ltd. | Matthew Gline CEO | $8.4M 289,774 shares | -2% | |
| 51Moderate | Roivant Sciences Ltd. | Jennifer Humes Chief Accounting Officer | $384k 13,538 shares | -14% | |
| 60Notable | Roivant Sciences Ltd. | Meghan Fitzgerald director | $1.9M 70,000 shares | -62% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.